Zinc Supplementation and Behçet's Syndrome

Tabriz University of Medical Sciences

Status

Completed

Conditions

Behcet Syndrome

Treatments

Dietary Supplement: Placebo

Dietary Supplement: Zinc gluconate

Study type

Interventional

Funder types

Other

Identifiers

NCT05098678

64693

Details and patient eligibility

About

To study the effects of zinc gluconate supplementation on patients with Behçet's syndrome, 50 patients will be randomly allocated to two groups: placebo group or zinc group (one tablet of 30 mg/day elemental zinc) for 12 weeks. All participants will be asked not to alter their diet, medication, and physical activity during the study. At the first and the end of the intervention, genes and proteins expression, the serum level of inflammatory factors, quality of life, disease activity, anthropometric measures, physical activity and serum level of zinc will be assessed and compared between groups.

Enrollment

50 patients

Sex

All

Ages

20 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age range 20 to 50 years (premenopausal woman)
Diagnosis of Behcet's disease by a rheumatologist according to IBCD (The International Criteria for Behcet's Disease)
Patients who want to participate in the study

Exclusion criteria

Pregnancy and lactation
History of diabetes and other chronic diseases
Smoking and alcohol consumption over the past year
History of other autoimmune diseases
Consumption of nutritional and antioxidant supplements over two months prior to the study